Streptococcus Pneumoniae Nasopharyngeal Carriage

Sponsor
Department of Clinical Research and Innovation (Other)
Overall Status
Unknown status
CT.gov ID
NCT01485029
Collaborator
(none)
500
1
1
12
41.6

Study Details

Study Description

Brief Summary

Antibiotic consumption and antimicrobial resistance remain notoriously high in France, particularly among children below three years of age. In France, the pneumococcal conjugate vaccine was officially recommended for all children under two in 2003, and consequently changes occurred in Streptococcus pneumoniae serotype distribution. Bacterial carriage among children attending day-care centres may result from vaccine- and antibiotic-driven selective pressure with possible repercussions on the community.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Nasopharyngeal (NP) aspirate
N/A

Detailed Description

Antibiotic consumption and antimicrobial resistance remain notoriously high in France, particularly among children below three years of age. In France, the pneumococcal conjugate vaccine was officially recommended for all children under two in 2003, and consequently changes occurred in Streptococcus pneumoniae serotype distribution. Bacterial carriage among children attending day-care centres may result from vaccine- and antibiotic-driven selective pressure with possible repercussions on the community.

To identify prevalence (rates) and trends in antibiotic resistance patterns in Streptococcus pneumoniae (SP) among children attending day-care centres, as well as antibiotic prescriptions and vaccine rates, nasopharyngeal (NP) carriage was monitored, by conducting five cross-sectional surveys from January to March 1999, 2002, 2004, 2006 and 2008 among these children in the area of the Alpes Maritimes, in South-Eastern France.

Interventions promoting prudent antibiotic use (PAU) took place in 2000 and since 2003, with temporary effectiveness but national prescription rates are reported to be currently increasing again. A new pneumococcal conjugate vaccine covering more serotypes (13-valent) now replaces the previous one. In this situation, a new cross-sectional survey in day-care centres with the same design may answer the following questions.

  • Increasing antibiotic susceptibility was observed during past successive surveys. Has this trend been sustained to this day?

  • Are antibiotics prescription rates among children attending day-care centres still decreasing, have they stabilized, or are they on the rise again reflecting recently reported national trends?

  • Regarding choice of antimicrobial treatment, are 3rd generation cephalosporin increasingly prescribed rather than aminopenicillins?

  • Is implementation of the new wider spectrum pneumococcal conjugate vaccine exerting changes on serotype distribution and thus on the nasopharyngeal ecosystem of these children? These parameters will be useful to renew, or even reinforce, and adapt professional guidelines and community-oriented messages concerning prudent antibiotic use.

Sub-study: Antibiotic-resistant enterobacteriaceae, initially observed in the hospital setting, are currently spreading within the community, especially extended-spectrum beta-lactamase-producing enterobacteriaceae, threatening antibiotic effectiveness in case of infection. Such infections with Enterobacteriaceae, in particular urinary tract infections, can occur among children. Prevalence rates of such carriage among children attending day-care centres is unknown, although they are highly exposed to antibiotics in relation with frequent respiratory tract infections, in particular to 3rd generation cephalosporins. To assess this prevalence rate, faecal samples from children attending day-care centres will be collected during the cross-sectional nasopharyngeal survey quoted above.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
500 participants
Allocation:
Randomized
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Prevention
Official Title:
Streptococcus Pneumoniae Nasopharyngeal Carriage Among Children Attending Day-care Centres in the Alpes Maritimes. Substudy: Enterobacterial Intestinal Carriage and Susceptibility to 3rd Generation Cephalosporins
Study Start Date :
Jan 1, 2012
Actual Primary Completion Date :
Apr 1, 2012
Anticipated Study Completion Date :
Jan 1, 2013

Arms and Interventions

Arm Intervention/Treatment
Experimental: NP children

Nasopharyngeal (NP) aspirate with a small flexible canule to obtain NP swabs

Procedure: Nasopharyngeal (NP) aspirate
Nasopharyngeal (NP) aspirate with a small flexible canule to obtain NP swabs

Outcome Measures

Primary Outcome Measures

  1. Streptococcus pneumoniae nasopharyngeal carriage among children attending day-care centres, and Streptococcus pneumoniae antibiotic susceptibility Substudy: Enterobacterial intestinal carriage and susceptibility to 3rd generation cephalosporins [one day]

Secondary Outcome Measures

  1. •Antibiotics prescriptions within the 3 previous months in children's health booklets and in a questionnaire completed by parents [one day]

  2. • Immunization status for pneumococcal conjugate vaccine PCV7-type vaccine from children's health books and from day care centres health files [one day]

  3. • Pneumococcal serotypes distribution compared to immunization status [one day]

  4. • Comparison of the data above with the previous five cross-sectional surveys [one day]

Eligibility Criteria

Criteria

Ages Eligible for Study:
3 Months to 4 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Children aged from 3 months to 4 years

  • Attending a day care center

  • Parents give informed consent

Exclusion Criteria:
  • parents refusal

Contacts and Locations

Locations

Site City State Country Postal Code
1 Hôpital Archet 1 Nice France 06200

Sponsors and Collaborators

  • Department of Clinical Research and Innovation

Investigators

  • Principal Investigator: Christian PRADIER, PU-PH, Centre Hospitalier Universitaire de Nice

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Department of Clinical Research and Innovation, Pr PRADIER, Centre Hospitalier Universitaire de Nice
ClinicalTrials.gov Identifier:
NCT01485029
Other Study ID Numbers:
  • 11-APN-01
First Posted:
Dec 5, 2011
Last Update Posted:
Dec 18, 2012
Last Verified:
Dec 1, 2011
Additional relevant MeSH terms:

Study Results

No Results Posted as of Dec 18, 2012